N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺
| 中文名稱 | N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺 |
|---|---|
| 中文同義詞 | N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺;化合物PD158780;PD 158780,ERBB RECEPTOR TYROSINE KINASE抑制劑;化合物PD158780,10 MM DMSO 溶液;抑制劑PD158780;抑制劑PD158780 |
| 英文名稱 | PD158780 |
| 英文同義詞 | N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine;Pyrido[3,4-d]pyriMidine-4,6-diaMine,N4-(3-broMophenyl)-N6-Methyl- (Related Reference);Pyrido[3,4-d]pyriMidine-4,6-diaMine,N4-(3-broMophenyl)-N6-Methyl-;PD 158780 solution;InSolution? PD 158780;PD 158780 - CAS 171179-06-9 - Calbiochem;InSolution PD 158780 - CAS 171179-06-9 - Calbiochem;PD 158780; PD-158780 |
| CAS號 | 171179-06-9 |
| 分子式 | C14H12BrN5 |
| 分子量 | 330.18 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 171179-06-9.mol |
| 結(jié)構(gòu)式 | ![N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺 結(jié)構(gòu)式](CAS/GIF/171179-06-9.gif) |
N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺 性質(zhì)
| 熔點 | 174.0 to 178.0 °C |
|---|---|
| 沸點 | 499.6±45.0 °C(Predicted) |
| 密度 | 1.611±0.06 g/cm3 (20 ºC 760 Torr) |
| 儲存條件 | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| 溶解度 | 二甲基亞砜：≥20mg/mL |
| 形態(tài) | 黃色固體 |
| 酸度系數(shù)(pKa) | 5.80±0.30(Predicted) |
| 顏色 | 粘黃色 |
| InChI | 1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20) |
| InChIKey | KFHMLBXBRCITHF-UHFFFAOYSA-N |
|
EGFR 8 μM (IC 50 , Cell Assay) |
ErbB2 49 nM (IC 50 , Cell Assay) |
ErbB3 52 nM (IC 50 , Cell Assay) |
ErbB4 52 nM (IC 50 , Cell Assay) |
PD158780 inhibits EGF receptor autophosphorylation in A431 human epidermoid carcinoma with IC 50 value of 13 nM. PD158780 is highly specific for the EGF receptor in Swiss 3T3 fibroblasts, inhibiting EGF-dependent receptor autophosphorylation and thymidine incorporation at low nanomolar concentrations while requiring micromolar levels for platelet-derived growth factor- and basic fibroblast growth factordependent processes. PD158780 inhibits heregulin-stimulated phosphorylation in the SK-BR-3 and MDAMB-453 breast carcinomas with IC 50 values of 49 and 52 nM, respectively, suggesting that the compound is active against other members of the EGF receptor family.
PD158780 is active against clone formation in several breast tumors having different expression patterns of the ErbB family. PD158780 shows good therapeutic effect against the A431 epidermoid carcinoma when administered either intraperitoneally or orally. PD158780 produces measurable, significant effects against a mouse fibroblast transfected with human EGFR. PD158780 produces a significant therapeutic effect against the estrogendependent MCF-7 breast carcinoma at equitoxic dose levels.
![N-(3-溴苯基)-6-氟-吡啶并[3,4-D]嘧啶-4-胺](/CAS/GIF/171179-03-6.gif)
171179-03-6
![N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺](/CAS/GIF/171179-06-9.gif)
171179-06-9
實施例60：N4-(3-溴苯基)-N6-甲基吡啶并[3,4-d]嘧啶-4,6-二胺的合成 將N-(3-溴苯基)-6-氟-吡啶并[3,4-D]嘧啶-4-胺（0.20g，0.63mmol）置于壓力容器中，加入甲胺的乙醇溶液，于100℃下反應(yīng)。反應(yīng)完成后，通過氧化鋁柱色譜進行純化，洗脫劑為二氯甲烷/甲醇（99:1，v/v），得到目標產(chǎn)物N4-(3-溴苯基)-N6-甲基吡啶并[3,4-d]嘧啶-4,6-二胺（0.07g，收率34%）。 1H NMR (DMSO) δ 9.69 (1H, s), 8.75 (1H, s), 8.41 (1H, s), 8.21 (1H, brs), 7.93 (1H, brd, J = 7.6 Hz), 7.41-7.28 (2H, m), 7.06 (1H, s), 6.82 (1H, q, J = 5.0 Hz), 4.95 (3H, d, J = 5.0 Hz)。
參考文獻：
[1] Patent: US5654307, 1997, A
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-18609 | N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺 PD158780 | 171179-06-9 | 5 mg | 675元 |
| 2026/06/05 | HY-18609 | N4-(3-溴苯基)-N6-甲基-吡啶并[3,4-D]嘧啶-4,6-二胺 PD158780 | 171179-06-9 | 10 mM * 1 mL in DMSO | 742元 |